U.S. Markets closed

BioNTech SE (BNTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
66.69+3.86 (+6.14%)
At close: 4:00PM EDT
Sign in to post a message.
  • C
    question: do any one know the suggested vaccine pricing for BioN? I read $19.95 and was wondering if that is a single shot or does that include the booster? thanks
  • H
    I wish Jason could post one useful post, instead of 24/7 @&&p
  • o
    I need a favor. Can someone investigate who has been selling a large bloc of shares right at open starting on 9/21,22,23,24,25? It has been consistent right at 9:30 am.
  • C
    If one vaccine is good, two may be better. right? i don't know.

    In any case, I am firmly in BNTX and have been studying the other vaccines as well so i am going to get rich, i might as well get rich to the power 2. I am not impressed with J&J due to its potential limits in revaccination. Not too excited about Moderna either as that's perhaps too similar to BNTX anyway. But how about NVAX?

    is there any reason that i should or should not buy a few of their shares?
  • C

    A Moderna analyst mani foroohar just downgraded moderna to $41 and basically said BioN is superior to jnj, moderna, and Astra based on timing and trial design. I am paraphrasing, but she cautioned about Other vaccines. Here is a piece:

    “Design of interim analyses favors BNT162b2 to hit on efficacy earlier than mRNA-1273, assuming a similar level of efficacy between the two vaccines."

    Secondly, increasing competition is a pushback, Foroohar said.“
  • H
    Good move, but no volume on bntx or Pfizer
  • V
    The price is still creeping up AH. I will be impressed if we go over 70 either today, or on Monday after the announcements on the 27th. That's because the next options to expire have open interest mostly above 70 and below 60.
  • F
    30% of volume yesterday was short. Compare to MRNA that was only 15%. Shorts interest in BNTX has been quite high the entire week. It looks like Traders enjoy playing short with BNTX.
  • P
    Wishing everyone a good day.
  • d
    d o
    we need more volume
  • N
    Helena Bourla told 60% chance having results by end of october.
  • Y
    Time to buy more, there is a reason why the stock is up, trust me on that.
    alot of happy faces next week.
  • s
    Pfizer Inc. should wait until at least late November before seeking FDA authorization of its COVID-19 vaccine to meet rigorous safety standards, more than 60 leading researchers and bioethicists said.

    The letter, obtained by Bloomberg Law and verified by six signatories, was sent Friday following reports that Pfizer's clinical trial will yield conclusive results in October. That would likely put the company ahead of Moderna Inc. and AstraZeneca PLC and other promising vaccine candidates.

    But the researchers said Pfizer's clinical trial needs to monitor participants for at least two months after they received the second dose. That would bring the New York-based pharmaceutical giant into at least late November before the Food and Drug Administration should consider granting an emergency use authorization, according to the letter.

    "To be successful, the public needs to have the utmost trust in the vaccine and the science behind it," the letter said. "Submission of an application for an EUA before this standard is met would severely erode public trust and set back efforts to achieve widespread vaccination."

    The scientists added that "a premature application would prolong the pandemic, with disastrous consequences."

    A Pfizer spokeswoman confirmed the company received the letter and that the company is working on a response. Pfizer signed a pledge earlier this month not to cut corners on a vaccine.

    The recommendation would put Pfizer's vaccine on the market after the presidential election and comes amid increasing concerns about the White House pressuring the FDA to rush a vaccine. The letter focused only on safety and rigor and didn't mention any concerns of political interference.

    The signatories of the letter include scientists from a variety of public health backgrounds, including: Joshua M. Sharfstein, vice dean for public health practice and community engagement at Johns Hopkins University and a former second-in-command at the FDA; Esther K. Choo, an emergency medicine physician and professor at Oregon Health & Science University; and Jeffrey R. Botkin, a University of Utah professor of pediatrics and medical ethics.
  • C
    BioNTec to Britain - No thank you, we won't be part of that HUMAN experiment.

    FRANKFURT (Reuters) - Pfizer's German development partner BioNTech on Thursday joined other leading COVID-19 vaccine developers in ruling out participation in British plans to test experimental inoculations by deliberately infecting trial volunteers.

    "BioNTech's vaccine candidate is not part of this study," a spokeswoman said.
  • H
    Is it really true that the CEO of PFE, Bourla say that by the end of October the Co. will know if the vaccine works ?
  • U
    Cuta Dolche Jason
    There's a pretty strong argument to be made that the coronavirus vaccine candidate that BioNTech and its partner Pfizer (NYSE:PFE) are developing is the leader right now. Bill Gates seems to think so.
    BioNTech and Pfizer are currently evaluating BNT162b2 in a pivotal late-stage clinical study. The companies anticipate that they'll be able to report preliminary results by the end of next month. At this point, BNT162b2 looks like the odds-on favorite to become the first coronavirus vaccine to win Food and Drug Administration emergency use authorization.
    If BNT162b2 is successful in late-stage testing, BioNTech stands to make a lot of money. It and Pfizer have already lined up a deal to supply at least 100 million doses of the vaccine to the U.S. and potentially up to 600 million doses. The partners also inked supply agreements with Canada and Japan. BioNTech and Fosun Pharma could also supply 10 million doses to Hong Kong and Macao.
    Success for BNT162b2 could also bode well for the rest of BioNTech's messenger RNA (mRNA) pipeline candidates. The biotech and its partner Roche Holdings are evaluating mRNA therapy BNT122 in phase 2 testing as a potential first-line treatment for melanoma. The companies are also evaluating BNT122 in a phase 1 clinical study for treating other solid tumors. In addition, BioNTech's pipeline includes six other early-stage mRNA candidates targeting various types of cancer.
    BioNTech isn't solely focused on mRNA technology, though. The company also has three antibody therapies in early-stage clinical testing for treating solid tumors and pancreatic cancer. It's partnering with Genmab on two of those programs. 
  • D
    Rumors about amazing news the stock should be up soon
  • k
    Are we back in the trend noted by Huntr....buy the open, sell the close. ?
  • o
    Fauci said covid vaccination could start in November. Gee I wonder which vaccine will be ready that early?
  • C
    report says JnJ vaccine is problematic as it is a one shot (no booster), but then the body tends to resist it after that. This means limited use for revaccination. Stay with the winner and the mRNA can be injected as many times as needed over years...